
Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab soravtansine in patients with folate receptor α–positive, platinum-resistant ovarian cancer.

Your AI-Trained Oncology Knowledge Connection!

Toon Van Gorp, MD, PhD, is from University Hospital Leuven Kefir Cancer Institute and BGOG, in Leuven, Belgium.